Purpose: Despite recent advances in the treatment of prurigo nodularis, conventional treatment suffers from a dilemma of poor efficacy. The clinical use of Janus kinase (JAK) inhibitors in the treatment of Prurigo nodularis has rarely been explored.
Patients And Methods: We present a case of prurigo nodularis successfully treated with, JAK inhibitor tofacitinib with no adverse effects.
Results: This case report of successful treatment shows a good clinical efficacy of using JAK inhibitor tofacitinib in the treatment of prurigo nodularis. Cytokines may be an important cause of prurigo nodularis.
Conclusion: JAK inhibitor tofacitinib may be a new option for the treatment of prurigo nodularis, especially for patients who have failed conventional treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956247 | PMC |
| http://dx.doi.org/10.2147/CCID.S354025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Disease severity and pruritus treatment outcomes in prurigo nodularis: A systematic review of randomized-controlled trials.
J Am Acad Dermatol
March 2025
Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. Electronic address:
Efficacy and Safety of Nemolizumab in Patients With Prurigo Nodularis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Cureus
February 2025
Cardiology, Pakistan Navy Station (PNS) Shifa, Karachi, PAK.
This meta-analysis evaluated the efficacy and safety of nemolizumab in treating prurigo nodularis through a systematic review of randomized controlled trials. A comprehensive literature search was conducted across multiple databases, including PubMed, Embase, Cochrane Library, and Web of Science, identifying relevant studies until January 5th 2025. Four randomized controlled trials involving 859 participants were included in the final analysis.
View Article and Find Full Text PDFSystemic barrier dysfunction in type 2 inflammation diseases: perspective in the skin, airways, and gastrointestinal tract.
Immunol Res
March 2025
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, Milan, Italy.
The epithelial barrier in different organs is the first line of defense against environmental insults and allergens, with type 2 immunity serving as a protective function. Genetic factors, and biological and chemical insults from the surrounding environment altered regulate epithelial homeostasis through disruption of epithelial tight junction proteins or dilated intercellular spaces. Recent studies suggest that epithelial barrier dysfunction contributes to pathologic alteration in diseases with type 2 immune dysregulation including (but not limited to) atopic dermatitis, prurigo nodularis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis.
View Article and Find Full Text PDFBreaking the Itch Cycle: Long-Term effects of Nemolizumab in Prurigo Nodularis.
Br J Dermatol
March 2025
Department of Dermatology, Medical Faculty, Medical College of Rzeszów University, 35-055 Rzeszów, Poland.
Abrocitinib as a novel therapeutic approach for refractory prurigo nodularis: real-world evidence.
Arch Dermatol Res
March 2025
Department of Pathology, Kocaeli University Faculty of Medicine, Kocaeli, Türkiye.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!